Note: This is an update to a January 2020 post to include Lupin's investigational agent in phase 3 trials. Roche’s reference product Lucentis® (ranibizumab) seems to be the next likely target for biosimilar competition. Sales of the drug in the US were last reported to be $1.5 billion in 2017, but Roche’s revenues from Lucentis … Continue reading Who Are the Key Lucentis Biosimilar Players to Watch?
Tag: FYB201
A Profile of a Lesser-Known Player in the Biosimilar Space: Polpharma Biologics
On occasion, we profile some biosimilar manufacturers about whom our readers may not be familiar. This generally refers to companies with products that are in earlier-stage research or those who simply have not been in the news as often as their colleagues. In this post, we highlight a European company, Polpharma Biologics. The drug maker … Continue reading A Profile of a Lesser-Known Player in the Biosimilar Space: Polpharma Biologics